NASDAQ:DYAX

Dyax (DYAX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$38.41
$38.41
50-Day Range
N/A
52-Week Range
$14.06
$38.56
Volume
N/A
Average Volume
5.25 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DYAX stock logo

About Dyax Stock (NASDAQ:DYAX)

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

DYAX Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
S-1: NutriBand Inc.
No more deaths recorded in Bristol
See More Headlines
Receive DYAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/28/2015
Today
4/24/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DYAX
CUSIP
26746E10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

DYAX Stock Analysis - Frequently Asked Questions

How were Dyax's earnings last quarter?

Dyax Corp (NASDAQ:DYAX) announced its quarterly earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The biopharmaceutical company earned $24.70 million during the quarter, compared to the consensus estimate of $24.96 million. The firm's revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.01) EPS.

What other stocks do shareholders of Dyax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyax investors own include (KRFT) (KRFT), ASML (ASML), Bank of Nova Scotia (BNS), DOW (DOW), Dover Motorsports (DVD), Novavax (NVAX), Prudential (PRU), Standard Chartered (STAN), Anthera Pharmaceuticals (ANTH) and Ariad Pharmaceuticals (ARIA).

This page (NASDAQ:DYAX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners